Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Randomized Experiments

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hospital-Level Variation in Antenatal Corticosteroids for Late Preterm Births.

medRxiv : the preprint server for health sciences·2026

Same author

Robotic vs laparoscopic interval cytoreductive surgery in stage III ovarian cancer: an analysis of the National Cancer Database.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Same author

Frequency of lymph node involvement in clinically early-stage low-grade serous ovarian cancer: a systematic review and meta-analysis.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Same author

Gynecologic cancers in veterans and military service members compared to non-veterans, 2004-2021: A National cancer database study.

Gynecologic oncology reports·2026

Same author

Antenatal Steroid Exposure among Late Preterm Births Following Updated Clinical Guidance.

medRxiv : the preprint server for health sciences·2026

Same author

Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Search research articles

Related Experiment Video

Updated: Nov 21, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

Facilitated cascade testing (FaCT): a randomized controlled trial.

Roni Nitecki¹, Haley A Moss², Catherine H Watson²

¹Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society

|January 14, 2021

Summary

This summary is machine-generated.

Facilitated cascade testing significantly increases genetic testing uptake in relatives of BRCA1/2 mutation carriers. This approach enhances hereditary cancer prevention by improving access to crucial genetic information for families.

Keywords:

BRCA1 protein BRCA2 protein ovarian cancer

More Related Videos

Computerized Adaptive Testing System of Functional Assessment of Stroke

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

Related Experiment Videos

Last Updated: Nov 21, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

Computerized Adaptive Testing System of Functional Assessment of Stroke

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

Area of Science:

Oncology
Genetics
Preventive Medicine

Background:

Cascade testing for hereditary cancer syndromes is underutilized.
Facilitated genetic testing shows promise for increasing uptake among at-risk relatives.

Purpose of the Study:

To compare the uptake of genetic testing in first-degree relatives of BRCA1/2 mutation carriers using a facilitated cascade testing strategy versus standard care.
To evaluate the efficacy of a multicomponent facilitated cascade testing intervention.

Main Methods:

A prospective, multi-institutional randomized trial (FaCT trial) comparing facilitated cascade testing with standard, proband-mediated information sharing.
Participants include first-degree relatives of patients with known BRCA1/2 mutations who have not undergone prior genetic testing.
The intervention group receives patient navigator support, an educational video, and accessible testing services.

Main Results:

The study aims to assess the proportion of relatives completing genetic testing within 6 months.
The primary endpoint is the comparison of genetic testing uptake between the facilitated intervention arm and the standard care arm.
The trial is designed to randomize 150 probands, expecting to enroll approximately 450 relatives.

Conclusions:

Facilitated cascade testing is hypothesized to significantly increase genetic testing uptake compared to standard care.
This strategy aims to improve primary cancer prevention by identifying more mutation carriers within families.
Results are anticipated by January 2024.